Pharmaceutical Report Library l Report Store l Pharma Intelligence

Generics: Regulatory Update

$2,995.00

Regulatory measures continue to shape the generics landscape. Cost-containment strategies continue to impact generics.

November 4, 2016

Find out more

Anemia in Chronic Kidney Disease Pricing & Reimbursement KOL Interview – US, Southwest

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into pricing and reimbursement dynamics and issues concerning anemia in chronic kidney disease, with a focus on the anticipated reimbursement of HIF stabilizers in the US.

June 30, 2020

Find out more

Company Analysis: Regeneron

$3,000.00

PharmaVitae explores Regeneron’s prescription pharmaceutical performance and outlook over 2019–29.

January 25, 2021

Find out more

Disease Analysis: Psoriatic Arthritis

Psoriatic arthritis is grouped with spondyloarthritis and is characterized by inflammation in the spine (spondylitis) and/or joints (arthritis). It is often preceded by a diagnosis of psoriasis by about 10 years. The disease may be characterized by joint pain, swelling, or morning stiffness, and about 80–90% of psoriatic arthritis patients experience nail lesions, which include pitting (dents) and onycholysis (detachment). Around 30% of individuals with psoriasis develop psoriatic arthritis.

March 30, 2022

Find out more

Entyvio

Entyvio (vedolizumab; Takeda) is a humanized monoclonal antibody approved for the treatment of Crohn’s disease and ulcerative colitis.

August 2, 2018

Find out more

Disease Analysis: Alzheimer’s Disease

Alzheimer’s disease is an irreversible, progressive, neurodegenerative disease that slowly affects memory, cognition, and function. It is a continuum of pathological changes in the brain that begin well before clinical symptoms emerge.

January 31, 2022

Find out more

Trogarzo

Trogarzo (ibalizumab; Theratechnologies/TaiMed Biologics) is a recombinant humanized monoclonal antibody approved for the treatment of HIV-1 infection. It targets the HIV-1 post-attachment process by binding one of the domains of the CD-4 protein, which inhibits a conformational change in CD-4 that is necessary to allow entry of HIV into T-cells.

July 28, 2019

Find out more

Market Spotlight: Osteoarthritis and Osteoarthritis Pain

$1,318.00

This Market Spotlight report covers the Osteoarthritis and Osteoarthritis Pain market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

May 19, 2022

Find out more

Diagnostic and Guided Interventional Cardiology Products Market

$4,750.00

This comprehensive medical market and technology report provides an overview and in-depth market analysis of diagnostic and guided interventional cardiology devices (specifically, transcatheter angiography, guidewire-based intravascular stenosis assessment, intracardiac echocardiography (ICE), intravascular ultrasound (IVUS), optical coherence tomography (OCT), and robotic-assisted surgical systems) used in the diagnosis of cardiovascular diseases (CVDs) and guidance of minimally invasive therapies.

July 31, 2017

Find out more

Company Analysis: Pfizer

$3,000.00

PharmaVitae explores Pfizer’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

August 28, 2020

Find out more

Kengreal

Kengreal (cangrelor; AstraZeneca) targets a previously unmet need in the acute treatment of

myocardial infarction (MI) patients receiving percutaneous coronary intervention (PCI) on account of

its intravenous formulation and quick onset of action.

April 14, 2016

Find out more

2015 Jardiance EMPA-REG CVOT Pulse

$599.00

This 5-question survey of 30 primary care physicians and 29 endocrinologists in the United States evaluates the impact of the EMPA-REG cardiovascular outcomes trial (CVOT) of SGLT2 inhibitor Jardiance (Boehringer, LLY).

November 1, 2015

Find out more

Lovenox

Lovenox (enoxaparin; Sanofi/Kaken Pharmaceutical) is a subcutaneous low molecular weight heparin approved for the prophylaxis of deep vein thrombosis (DVT)…

August 2, 2016

Find out more

Market Spotlight: Chemotherapy-Induced Anemia

$1,318.00

This Market Spotlight report covers the chemotherapy-induced anemia market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

May 5, 2022

Find out more

Odefsey

Odefsey ([rilpivirine + emtricitabine + tenofovir alafenamide (TAF)]; Gilead/Johnson & Johnson) is a single-tablet regimen approved in the US and five major EU markets (France, Germany, Italy, Spain, and the UK) for the treatment of HIV-1 infection. Odefsey contains Gilead’s nucleos(t)ide reverse transcriptase inhibitors (NRTIs) TAF and Emtriva (emtricitabine), and Johnson & Johnson’s non-nucleoside reverse transcriptase inhibitor Edurant (rilpivirine; Johnson & Johnson).

June 28, 2019

Find out more

Report library

Generics: Regulatory Update

Anemia in Chronic Kidney Disease Pricing & Reimbursement KOL Interview – US, Southwest

Company Analysis: Regeneron

Disease Analysis: Psoriatic Arthritis

Entyvio

Disease Analysis: Alzheimer’s Disease

Trogarzo

Market Spotlight: Osteoarthritis and Osteoarthritis Pain

Diagnostic and Guided Interventional Cardiology Products Market

Company Analysis: Pfizer

Kengreal

2015 Jardiance EMPA-REG CVOT Pulse

Lovenox

Market Spotlight: Chemotherapy-Induced Anemia

Odefsey